MY185593A - Cortistatin analogues for the treatment of inflammatory and/or immune diseases - Google Patents

Cortistatin analogues for the treatment of inflammatory and/or immune diseases

Info

Publication number
MY185593A
MY185593A MYPI2016000336A MYPI2016000336A MY185593A MY 185593 A MY185593 A MY 185593A MY PI2016000336 A MYPI2016000336 A MY PI2016000336A MY PI2016000336 A MYPI2016000336 A MY PI2016000336A MY 185593 A MY185593 A MY 185593A
Authority
MY
Malaysia
Prior art keywords
cortistatin
inflammatory
treatment
immune diseases
analogues
Prior art date
Application number
MYPI2016000336A
Other languages
English (en)
Inventor
Carneado Jimena Fernandez
Obiols Berta Ponsati
Josep Farrera-Sinfreu
Due?A Antonio Parente
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of MY185593A publication Critical patent/MY185593A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Birds (AREA)
MYPI2016000336A 2013-09-18 2014-09-17 Cortistatin analogues for the treatment of inflammatory and/or immune diseases MY185593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382361 2013-09-18
PCT/EP2014/069842 WO2015040089A1 (en) 2013-09-18 2014-09-17 Co rti statin analogues for the treatment of inflammatory and/or immune diseases

Publications (1)

Publication Number Publication Date
MY185593A true MY185593A (en) 2021-05-24

Family

ID=49880656

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000336A MY185593A (en) 2013-09-18 2014-09-17 Cortistatin analogues for the treatment of inflammatory and/or immune diseases

Country Status (23)

Country Link
US (1) US12297294B2 (https=)
EP (1) EP3046933B1 (https=)
JP (1) JP6989260B2 (https=)
KR (1) KR102285939B1 (https=)
CN (1) CN105579467B (https=)
AU (1) AU2014323131B2 (https=)
BR (1) BR112016005731B1 (https=)
CA (1) CA2921324C (https=)
CL (1) CL2016000392A1 (https=)
DK (1) DK3046933T3 (https=)
ES (1) ES2728319T3 (https=)
HU (1) HUE043206T2 (https=)
IL (1) IL244317B (https=)
LT (1) LT3046933T (https=)
MX (1) MX368373B (https=)
MY (1) MY185593A (https=)
NZ (1) NZ717035A (https=)
PL (1) PL3046933T3 (https=)
PT (1) PT3046933T (https=)
RU (1) RU2678315C2 (https=)
SG (1) SG11201601036UA (https=)
UA (1) UA119148C2 (https=)
WO (1) WO2015040089A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3648750A4 (en) 2017-07-05 2021-05-26 Wisconsin Alumni Research Foundation MINERAL-COATED MICROPARTICLE FOR THE SIMULTANEOUS ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES WITH NUCLEIC ACIDS TO IMPROVE THE GENERAL TRANSFER RESULTS
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
SG11202006782YA (en) * 2018-01-31 2020-08-28 Twi Pharmaceuticals Inc Topical formulations comprising tofacitinib
JP7374117B2 (ja) 2018-03-29 2023-11-06 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチドおよびその使用
RU2698451C1 (ru) * 2018-07-02 2019-08-27 Павел Александрович Храмов Средство и способ для лечения нейросенсорной тугоухости
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
JP7692910B2 (ja) 2019-12-05 2025-06-16 ベセエネ ペプチドス エセ.ア. 癌および/または転移の治療のためのペプチド
CN111297876B (zh) * 2020-01-16 2021-04-27 武汉理工大学 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法
CN115120702A (zh) * 2020-03-30 2022-09-30 山东大学齐鲁医院 皮质抑素14在制备银屑病治疗药物中的应用
CN113797314B (zh) * 2021-09-29 2023-08-22 山东大学齐鲁医院 Cst多肽在制备股骨头坏死治疗药物中的应用
CN114949174B (zh) * 2022-07-19 2025-09-30 山东大学齐鲁医院 Cst-14在制备糖尿病皮肤溃疡、破损治疗药物中的应用
CN117866953B (zh) * 2023-03-02 2025-03-07 江西省人民医院 靶向生长激素释放抑制激素基因的shRNA及其医药应用
CN117567554B (zh) * 2023-11-16 2025-03-07 中国科学技术大学 一种荷载抗炎药的凝胶因子、水凝胶及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2978697A (en) * 1996-06-07 1998-01-05 Takeda Chemical Industries Ltd. Novel peptide, process for the production of the same, and use of the same
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
EP2913056A1 (en) 2006-01-05 2015-09-02 The University of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007082980A1 (es) * 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2009043523A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
ES2351569B8 (es) 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.

Also Published As

Publication number Publication date
UA119148C2 (uk) 2019-05-10
US12297294B2 (en) 2025-05-13
DK3046933T3 (da) 2019-05-13
WO2015040089A1 (en) 2015-03-26
CA2921324A1 (en) 2015-03-26
IL244317B (en) 2020-06-30
JP6989260B2 (ja) 2022-01-05
AU2014323131B2 (en) 2018-08-09
CL2016000392A1 (es) 2016-11-11
EP3046933A1 (en) 2016-07-27
MX368373B (es) 2019-09-27
CN105579467A (zh) 2016-05-11
HUE043206T2 (hu) 2019-08-28
ES2728319T3 (es) 2019-10-23
HK1218122A1 (zh) 2017-02-03
RU2016109410A (ru) 2017-10-18
RU2678315C2 (ru) 2019-01-28
CN105579467B (zh) 2021-03-09
KR20160054512A (ko) 2016-05-16
SG11201601036UA (en) 2016-04-28
BR112016005731B1 (pt) 2023-01-17
EP3046933B1 (en) 2019-02-27
RU2016109410A3 (https=) 2018-05-24
IL244317A0 (en) 2016-04-21
MX2016003490A (es) 2016-07-06
JP2016535760A (ja) 2016-11-17
KR102285939B1 (ko) 2021-08-05
CA2921324C (en) 2022-11-22
US20160185822A1 (en) 2016-06-30
PT3046933T (pt) 2019-05-31
NZ717035A (en) 2019-11-29
LT3046933T (lt) 2019-05-27
AU2014323131A1 (en) 2016-03-10
BR112016005731A2 (https=) 2017-08-01
PL3046933T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
MY185593A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
MY172578A (en) Oral dosing of glp-1 compounds
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX365864B (es) Inhibidores de bromodominio biciclicos novedosos.
MX371187B (es) Péptidos terapéuticos.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
PH12017500864A1 (en) Anti-notch1 antibodies
MX2015015249A (es) Peptidos terapeuticos.
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
IN2014DN09717A (https=)
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations